Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics

From: Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer

Total patients (n = 36)
Age, median (IQR), years 63 (10)
Tumor classification  
cT1 27 (75.0%)
cT2 9 (25.0%)
Gleason Score  
3-5 8 (22.2%)
6 23 (63.9%)
7 5 (13.9%)
Pre-treatment PSA  
≤10 ng/mL 31 (86.1%)
>10 ng/mL 5 (13.9%)
Percent positive biopsies  
≤ 50% 17 (47.2%)
> 50% 14 (38.9%)
Unknown 5 (13.9%)
Risk group  
Low 28 (77.8%)
Intermediate 8 (22.2%)
  1. Abbreviations: PSA prostate-specific antigen, IQR interquartile range.